- Home
- AUTL vs SOR Comparison
AUTL vs SOR Comparison
Compare AUTL & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- SOR
- Stock Information
- Founded
- AUTL 2014
- SOR 1968
- Country
- AUTL United Kingdom
- SOR United States
- Employees
- AUTL N/A
- SOR N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- SOR Investment Managers
- Sector
- AUTL Health Care
- SOR Finance
- Exchange
- AUTL Nasdaq
- SOR Nasdaq
- Market Cap
- AUTL 360.6M
- SOR 328.9M
- IPO Year
- AUTL 2018
- SOR N/A
- Fundamental
- Price
- AUTL $1.32
- SOR $41.75
- Analyst Decision
- AUTL Strong Buy
- SOR
- Analyst Count
- AUTL 5
- SOR 0
- Target Price
- AUTL $9.32
- SOR N/A
- AVG Volume (30 Days)
- AUTL 2.4M
- SOR 16.2K
- Earning Date
- AUTL 05-08-2025
- SOR 01-01-0001
- Dividend Yield
- AUTL N/A
- SOR 7.24%
- EPS Growth
- AUTL N/A
- SOR N/A
- EPS
- AUTL N/A
- SOR 6.50
- Revenue
- AUTL $9,011,000.00
- SOR N/A
- Revenue This Year
- AUTL $277.74
- SOR N/A
- Revenue Next Year
- AUTL $221.89
- SOR N/A
- P/E Ratio
- AUTL N/A
- SOR $6.41
- Revenue Growth
- AUTL N/A
- SOR N/A
- 52 Week Low
- AUTL $1.11
- SOR $36.41
- 52 Week High
- AUTL $5.00
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- AUTL 45.63
- SOR 55.53
- Support Level
- AUTL $1.15
- SOR $41.11
- Resistance Level
- AUTL $1.44
- SOR $42.58
- Average True Range (ATR)
- AUTL 0.14
- SOR 1.03
- MACD
- AUTL 0.01
- SOR 0.11
- Stochastic Oscillator
- AUTL 29.82
- SOR 66.40
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.